Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

ClinicalTrials.gov ID: NCT01278615

Public ClinicalTrials.gov record NCT01278615. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 11:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Single-Arm Phase II Clinical Trial With the Novel MEK Inhibitor AZD-6244 for the Treatment of MCT-1 Related Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Study identification

NCT ID
NCT01278615
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
16 participants

Conditions and interventions

Interventions

  • Laboratory Biomarker Analysis Other
  • Selumetinib Drug

Other · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2010
Primary completion
Jan 31, 2014
Completion
Apr 30, 2014
Last update posted
Feb 2, 2016

2010 – 2014

United States locations

U.S. sites
16
U.S. states
8
U.S. cities
15
Facility City State ZIP Site status
Northwestern University Chicago Illinois 60611
University of Chicago Comprehensive Cancer Center Chicago Illinois 60637
Decatur Memorial Hospital Decatur Illinois 62526
NorthShore University HealthSystem-Evanston Hospital Evanston Illinois 60201
Ingalls Memorial Hospital Harvey Illinois 60426
Illinois CancerCare-Peoria Peoria Illinois 61615
Southern Illinois University Springfield Illinois 62702
Fort Wayne Medical Oncology and Hematology Inc-Parkview Fort Wayne Indiana 46845
Indiana University/Melvin and Bren Simon Cancer Center Indianapolis Indiana 46202
University of Maryland/Greenebaum Cancer Center Baltimore Maryland 21201
Tufts Medical Center Boston Massachusetts 02111
University of Massachusetts Memorial Health Care Worcester Massachusetts 01605
University of Michigan Ann Arbor Michigan 48109
Saint John's Mercy Medical Center St Louis Missouri 63141
Weill Medical College of Cornell University New York New York 10065
M D Anderson Cancer Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01278615, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 2, 2016 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01278615 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →